Integra EVP granted 41,783 RSUs; 5,420 shares withheld

INTEGRA LIFESCIENCES HOLDINGS CORP executive Chantal Veillon-Berteloot, EVP & CHRO, reported an equity compensation grant and related tax withholding.

Rhea-AI Filing Summary

INTEGRA LIFESCIENCES HOLDINGS CORP executive Chantal Veillon-Berteloot, EVP & CHRO, reported an equity compensation grant and related tax withholding. She received 41,783 restricted stock units, each representing one share of common stock. The award will vest 33% on the first and second anniversaries and 34% on the third anniversary of the 3/11/2026 grant date.

On the same date, 5,420 shares of common stock were disposed of at $9.61 per share to satisfy tax liabilities through share withholding, rather than an open-market sale. Following these transactions, Veillon-Berteloot directly owns 22,227 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Veillon-Berteloot Chantal

Role EVP & CHRO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	41,783	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	5,420	$9.61	$52K

Holdings After Transaction: Restricted Stock Units — 41,783 contracts (Direct); Common Stock — 22,227 shares (Direct)

Footnotes (1)

1. F1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Integra Lifesciences (IART) executive Chantal Veillon-Berteloot report on this Form 4?

She reported an equity grant and related tax withholding. Veillon-Berteloot received 41,783 restricted stock units and had 5,420 common shares withheld to cover tax obligations, leaving her with 22,227 directly owned common shares after the transactions.

How many restricted stock units did the Integra Lifesciences (IART) EVP & CHRO receive?

She received 41,783 restricted stock units. Each restricted stock unit represents one share of common stock, providing deferred equity compensation that will vest over time according to a schedule tied to anniversaries of the March 11, 2026 grant date.

What is the vesting schedule for Chantal Veillon-Berteloot’s IART restricted stock units?

The 41,783 restricted stock units vest over three years. They vest 33% on the first anniversary, 33% on the second anniversary, and 34% on the third anniversary of the March 11, 2026 grant date, subject to the award’s terms.

Why were 5,420 shares of Integra Lifesciences (IART) common stock disposed of in this filing?

The 5,420 common shares were disposed of to pay tax liabilities. This was done through share withholding at a price of $9.61 per share, a non-market transaction classified as payment of tax liability by delivering securities rather than an open-market sale.

How many Integra Lifesciences (IART) common shares does Chantal Veillon-Berteloot hold after these transactions?

After the reported transactions, she directly holds 22,227 common shares. This reflects her position following the 5,420-share tax-withholding disposition, as disclosed in the Form 4’s post-transaction ownership field for her common stock holdings.

Is the Integra Lifesciences (IART) Form 4 transaction an open-market buy or sell?

The filing does not show any open-market buy or sell. It reports an equity award of 41,783 restricted stock units and a tax-withholding disposition of 5,420 common shares, classified as payment of tax liability by delivering securities, not a market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Veillon-Berteloot Chantal

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CHRO

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		F		5,420	D	$9.61	22,227	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		41,783		(1)	(1)	Common Stock	41,783	$0	41,783	D

Explanation of Responses:

1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

Remarks:

	/s/ Michael D. Hutchinson; Attorney-in-Fact for Chantal Veillon-Berteloot	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.